CYCC - Cyclacel Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
0
0
150
0
843
Operating Expenses
Research Development
4,658
4,658
4,327
4,237
9,477
Selling General and Administrative
5,024
5,024
5,371
5,254
5,516
Total Operating Expenses
9,682
9,682
9,698
9,491
14,993
Operating Income or Loss
-9,682
-9,682
-9,548
-9,491
-14,150
Total Other Income/Expenses Net
332
332
592
910
339
Income Before Tax
-9,126
-9,126
-8,625
-8,463
-13,774
Income Tax Expense
-1,296
-1,296
-1,337
-993
-1,983
Income from Continuing Operations
-7,830
-7,830
-7,288
-7,470
-11,791
Net Income
-7,830
-7,830
-7,288
-7,470
-11,791
Net Income available to common shareholders
-8,031
-8,031
-7,489
-14,846
-11,991
Basic EPS
-
-
-0.62
-1.95
-3.50
Diluted EPS
-
-
-0.62
-1.95
-3.50
Basic Average Shares
-
-
12,094
7,631
3,425
Diluted Average Shares
-
-
12,094
7,631
3,425
EBITDA
-
-9,662
-9,519
-9,459
-14,017